As we enter the final trading week of February, public biotech companies are maintaining their relentless performance on the capital markets. The BioWorld Blue Chip Index, for example, is up almost 20 percent in value since the start of the new year. The price-weighted index that includes many of the industry’s leading biotechnology companies outperformed the Dow Jones Industrial average, which recorded a 3 percent drop and the Nasdaq Composite index, which was up 2 percent in the same period.